hengrui glp 1 China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes China's Hengrui/Kailera duo just filed
Description
Lets separate guesses from facts.
A double-blind, placebo-controlled, randomized trial of probiotics for primary prevention of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
GLP-1 medications have benefits and risks for fertility patients
Full article here: #orthopedics #sportsmedicine #biologics #peptides #medtech #clinicalresearch #innovation #jointpreservation
